On the cancer side, in vitro and in vivo downregulations of ANGPTL3 have been described in different models of oral squamous cancer [34], colorectal cancer [35], hepatocellular carcinoma [36] and epithelial high‐grade serous ovarian cancer [37], positioning ANGPTL3 and its inhibition as a promising target against cancer. The gene discussed is ANGPTL3; the disease is colorectal cancer.